Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
6.277
Zitationen
15
Autoren
2006
Jahr
Abstract
In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).
Ähnliche Arbeiten
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 · 7.183 Zit.
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA
1965 · 6.106 Zit.
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
2004 · 6.010 Zit.
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
2010 · 5.531 Zit.
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
2012 · 5.380 Zit.
Autoren
Institutionen
- Royal Marsden Hospital(GB)
- Royal Marsden NHS Foundation Trust(GB)
- Medical Research Council(GB)
- Leiden University Medical Center(NL)
- Aberdeen Royal Infirmary(GB)
- The Christie Hospital(GB)
- St George's Hospital(GB)
- At Bristol(GB)
- Southampton General Hospital(GB)
- Clatterbridge Cancer Centre NHS Foundation Trust(GB)